In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

The technology described uses a nanomechanical platform and tiny cantilevers to detect multiple HIV antigens at high sensitivity in a matter of minutes. These silicon cantilevers are cheap and easy to ...

The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

Many pathogens evade the host's immune response by periodically changing their surface antigens so that existing antibodies no longer recognize them. "This strategy is known as antigenic variation ...

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids. They ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.